The stock of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has decreased by -4.98 when compared to last closing price of 8.84. Despite this, the company has experienced a -13.58% fall in its stock price over the last five trading sessions. The Motley Fool reported 2023-09-18 that Aurinia Pharmaceuticals, an autoimmune disease specialist, is trading lower on high volume today. The biotech’s shares have been trading at a premium all year long.
Is It Worth Investing in Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) Right Now?
, and the 36-month beta value for AUPH is at 1.25. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
The average price suggested by analysts for AUPH is $14.00, which is $5.6 above the current market price. The public float for AUPH is 133.37M, and currently, shorts hold a 10.46% of that float. The average trading volume for AUPH on September 19, 2023 was 2.15M shares.
AUPH’s Market Performance
AUPH’s stock has seen a -13.58% decrease for the week, with a -11.49% drop in the past month and a -12.77% fall in the past quarter. The volatility ratio for the week is 4.98%, and the volatility levels for the past 30 days are at 4.28% for Aurinia Pharmaceuticals Inc. The simple moving average for the last 20 days is -10.37% for AUPH stock, with a simple moving average of -8.24% for the last 200 days.
AUPH Trading at -16.70% from the 50-Day Moving Average
After a stumble in the market that brought AUPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.42% of loss for the given period.
Volatility was left at 4.28%, however, over the last 30 days, the volatility rate increased by 4.98%, as shares sank -14.20% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.37% lower at present.
During the last 5 trading sessions, AUPH fell by -13.58%, which changed the moving average for the period of 200-days by +69.70% in comparison to the 20-day moving average, which settled at $9.30. In addition, Aurinia Pharmaceuticals Inc. saw 94.44% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AUPH starting from Jayne David R.W., who sale 8,733 shares at the price of $11.26 back on May 23. After this action, Jayne David R.W. now owns 49,310 shares of Aurinia Pharmaceuticals Inc., valued at $98,334 using the latest closing price.
MacKay-Dunn R. Hector, the Director of Aurinia Pharmaceuticals Inc., sale 4,818 shares at $11.26 during a trade that took place back on May 23, which means that MacKay-Dunn R. Hector is holding 24,225 shares at $54,251 based on the most recent closing price.
Stock Fundamentals for AUPH
Current profitability levels for the company are sitting at:
- -84.30 for the present operating margin
- +95.77 for the gross margin
The net margin for Aurinia Pharmaceuticals Inc. stands at -80.71. The total capital return value is set at -25.07, while invested capital returns managed to touch -24.06. Equity return is now at value -18.10, with -14.80 for asset returns.
Based on Aurinia Pharmaceuticals Inc. (AUPH), the company’s capital structure generated 1.99 points at debt to equity in total, while total debt to capital is 1.96. Total debt to assets is 1.72, with long-term debt to equity ratio resting at 1.76. Finally, the long-term debt to capital ratio is 1.73.
When we switch over and look at the enterprise to sales, we see a ratio of 5.54, with the company’s debt to enterprise value settled at 0.03. The receivables turnover for the company is 9.28 and the total asset turnover is 0.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.60.
Conclusion
In conclusion, Aurinia Pharmaceuticals Inc. (AUPH) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
